Protara Therapeutics, Inc.

NASDAQ•TARA

CEO: Mr. Jesse Shefferman

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-10-22

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Contact Information

345 Park Avenue South, 3rd Floor, New York, NY, 10010, United States

646-844-0337

www.protaratx.com

Market Cap

$210.31M

P/E (TTM)

-4.3

17.2

Dividend Yield

52W High

$7.82

52W Low

$2.77

52W Range

53%

Rank68Top 98.2%

1.3

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.38+0.00%

4-Quarter Trend

FCF

-$16.97M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

R&D Expenses Increased Research and development expenses reached $42.6M USD, up $10.9M USD, driven by ADVANCED-2/3 and THRIVE-3 trial costs.

Operating Cash Used Grew Cash used in operating activities was $(56.4)M USD, reflecting increased net loss of $(57.4)M USD for the year.

NMIBC Trial Enrollment Advances Registrational ADVANCED-2 Cohort B enrollment completion expected H2 2026; initiating ADVANCED-3 trial H2 2026.

TARA-002 LM Data Strong STARBORN-1 interim data showed 83% CR rate in macrocystic LMs patients; enrollment completes H2 2026.

Risk Factors

No Revenue, Significant Losses Never generated revenue; expects increasing operating losses for foreseeable future; profitability achievement remains highly speculative.

Future Financing Required Substantial additional funds required for costly clinical trials; future capital raising may be costly or unavailable.

FDA Approval Delays Risk Disruptions at FDA may extend review times; substantial uncertainty exists regarding new regulatory initiatives impacting approvals.

Product Adoption Challenges Approved products face significant competition; commercial success depends on broad adoption despite existing therapies.

Outlook

Advance NMIBC Registrational Trials Complete ADVANCED-2 Cohort B enrollment; initiate ADVANCED-3 registrational trial for BCG-Naïve NMIBC patients H2 2026.

Progress IV Choline Chloride Progressing THRIVE-3 seamless Phase 2b/3 trial assessing efficacy and safety in patients receiving long-term PS.

Confirm LM Registrational Pathway Complete STARBORN-1 Phase 2 enrollment H2 2026; meet FDA H1 2026 to determine registrational pathway for LMs.

Build Commercial Infrastructure Intend to build commercial infrastructure to successfully launch approved oncology and rare disease products in key geographies.

Peer Comparison

Revenue (TTM)

GNFT

$126.71M

+9.8%

CDXS

$70.39M

+18.6%

IVVD

$53.43M

+110.5%

Gross Margin (Latest Quarter)

GNFT

100.0%

+0.0pp

ASMB

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SLS	$717.91M	-22.4	-95.2%	1.2%
ASMB	$451.26M	-5.7	-59.0%	1.1%
GNFT	$445.68M	-11.0	-63.7%	64.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026

EPS:-$0.33

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data